An interventional study of Ergospirometry in Cancer Therapy-related Cardiovascular Toxicity, Childhood Cancer and Chemotherapeutic Toxicity, sponsored by Centre Hospitalier Universitaire de Liege. Not yet recruiting. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Centre Hospitalier Universitaire de Liege · Not applicable, Interventional, and Diagnostic
The goal of this prospective interventional study is to improve the detection of subclinical chronic Cancer Therapy-Related Cardiovascular Toxicity (CTRCT) and evaluate the added value of advanced cardioechography, ergospirometry, and specific biomarkers in pediatric cancer survivors (aged 2 to 25) who received potentially cardiotoxic treatments (chemotherapy/thoracic radiotherapy). The main questions it aims to answer are:
At time of follow-up, if they agree, participants will:
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's planned enrollment of 100 is above the median of 50 across 7,253 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Centre Hospitalier Universitaire de Liege is the lead sponsor of 37 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients aged 2 to 25 years followed at CHU de Liège, who have received potentially cardiotoxic treatment (chemotherapy and/or thoracic radiotherapy) for pediatric cancer or bone marrow transplantation since January 1st, 2016 and are in remission for at least 1 year.
Diagnostic Test: Ergospirometry
Completion of validated, age-appropriate quality of life scales and physical activity assessment forms. Patients over 8 years of age will perform a standardized cardiopulmonary exercise test (CPET / ergospirometry) on a treadmill. Seven-day continuous monitoring using a wearable accelerometer. Collection of a 10 mL blood sample (one EDTA tube and one serum-clotting tube), to be centrifuged and stored at -80°C in the CHU de Liège "BHUL" biobank.
Also known as: Accelerometer Data, Biology sample, quality of life and physical activity validated evaluation forms
EKG anomaly
Presence of arrhythmia, prolonged QTc interval, or conduction disorders.
Time frame: At inclusion (single study visit)
Echocardiography anomaly: systolic dysfunction
Systolic dysfunction: LVEF \< 55% or a relative decrease of \>15%.
Time frame: At inclusion (single study visit)
Echocardiography anomaly: diastolic dysfunction
Based on standardized pediatric values : * E/A ratioaverage * E/e' \> 14 * e' velocities * LA volume index \> 32 mL/m².
Time frame: At inclusion (single study visit)
Echocardiography anomaly: Significant alteration in myocardial deformation
GLS decrease \> 15%
Time frame: At inclusion (single study visit)
Echocardiography anomaly: myocardial work indices
abnormal Myocardial Work indices
Time frame: At inclusion (single study visit)
Echocardiography anomaly: valvular disease or heart inflammation
Structural/Inflammatory damage: Significant valvular disease, or signs of acute/chronic pericarditis and myocarditis.
Time frame: At inclusion (single study visit)
Cardiopulmonary Exercise Testing (CPET): Impaired functional capacity
defined as peak VO2 \< 85% or maximal workload \< 85% of predicted theoretical values.
Time frame: At inclusion (single study visit)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Liege